SCHEMBL3311167

SCHEMBL3311167

CCOC(=O)[C@H](N)Cc1cc(Cl)c(N)c(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 8/20 0.41
ADRB1 P08588 1/20 0.40
CPB2 Q96IY4 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MLNR O43193 1/20 0.36
NR3C1 P04150 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
TPH1 P17752 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
SLC6A2 P23975 1/20 0.36
AGTR1 P30556 1/20 0.36
SLC6A4 P31645 1/20 0.36
CCKAR P32238 1/20 0.36
MC3R P41968 1/20 0.36
HTR3A P46098 1/20 0.36
SLC6A3 Q01959 1/20 0.36
PDE4D Q08499 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310473 1.00 ADRB2 (0.41) ADRB2ADRB1CPB2MEN1KMT2A
SCHEMBL3314970 0.91 EPHX2 (0.37) ADRB2MLNRNR3C1ADORA3TPH1
SCHEMBL1206838 0.88 ADRB2 (0.41) ADRB2ADRB1CPB2MEN1KMT2A
SCHEMBL5234664 0.83 CPB2 (0.40) CPB2TPH1HSD11B1HPGD
SCHEMBL3309854 0.83 GRB2 (0.44) ADRB2ADRB1MEN1KMT2AADORA3
SCHEMBL3309849 0.83 GRB2 (0.44) ADRB2ADRB1MEN1KMT2AADORA3
Hydrochloric Acid SCHEMBL3311854 0.82 GRB2 (0.43) ADRB2ADRB1MEN1KMT2AADORA3
SCHEMBL5235272 0.81 THRB (0.40) CPB2MEN1KMT2ANR3C1ADORA3
SCHEMBL1205505 0.79 ADRB2 (0.46) ADRB2ADRB1HPGDPPARGPPARA
SCHEMBL3872154 0.77 GPR35 (0.42) MEN1KMT2APPARGGPR35EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113411-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-05-06 US disclosed
EP-1558600-B1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA (DE) 2008-05-07 EP disclosed
EP-1737842-A1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005100343-A1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113411-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA ADRB2 63/4885ADRB1 39/4885CPB2 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.